Amoxicillin Clavulanate in Treatment of Acute Otitis Media
Information source: University of Turku
Information obtained from ClinicalTrials.gov on November 03, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Otitis Media
Intervention: amoxicillin-clavulanate (Drug); Placebo (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Turku Official(s) and/or principal investigator(s): Aino Ruohola, MD, PhD, Principal Investigator, Affiliation: Pediatrician
Overall contact: Aino Ruohola, MD, PhD, Phone: +358 - 40 - 738 7358, Email: aino.ruohola@utu.fi
Summary
This is a prospective, randomized, double-blind, placebo controlled one-center study carried
out in primary care setting of the health center of City of Turku, Finland. The study
patients will be allocated to one of the two parallel treatment groups
(amoxicillin-clavulanate or placebo). The hypothesis is that the symptoms and signs of acute
otitis media are resolved more effectively with antimicrobial treatment than with placebo.
Furthermore, this study aims at finding out prognostic factors that could help to direct
antimicrobial treatment for correct subgroups of young patients.
Clinical Details
Official title: Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Primary outcome: Compare time to treatment failure in children receiving amoxicillin-clavulanate to children receiving placebo
Secondary outcome: Time to resolution of symptoms in children receiving amoxicillin-clavulanate to children receiving placeboTime to resolution of acute inflammatory signs of middle ear Compare the 2 treatment groups regarding the doses of analgesic medication and number of days analgesics are administered by children's parents Compare the 2 treatment groups regarding the number of days with absenteeism from day care and/or parental absenteeism from work Compare the incidence of adverse events accompanying the 2 treatment regimens Time to resolution of middle ear fluid in the ear(s) that is affected on study day 1 Time to relapse of acute otitis media Time to first reinfection of acute otitis media
Eligibility
Minimum age: 6 Months.
Maximum age: 35 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Acute otitis media
- Age 6 - 35 mo
Exclusion Criteria:
- Spontaneous perforation of the tympanic membrane and drainage
- Systemic or nasal corticosteroid therapy within 3 preceding days
- Antihistamine therapy with 3 preceding days
- Oseltamivir therapy within 3 preceding days
- Allergy to amoxicillin/penicillin
- Tympanostomy tube present in tympanic membrane
- Clinical evidence of infection requiring systemic antimicrobial treatment
- Documented Ebstein Barr virus infection within 7 preceding days
- Down syndrome or other condition to affect middle ear infections
- Known immunodeficiency
- Vomiting or another symptom to violate per oral dosage
- Poor parental co-operation due to language or other reasons
- Use of any investigational drugs during the 4 preceding weeks
Locations and Contacts
Aino Ruohola, MD, PhD, Phone: +358 - 40 - 738 7358, Email: aino.ruohola@utu.fi
Department of Pediatrics, Turku University Hospital, Turku 20521, Finland; Recruiting Aino Ruohola, MD, PhD, Principal Investigator
Additional Information
Starting date: March 2006
Ending date: December 2009
Last updated: August 26, 2008
|